GENOSCIENCE PHARMA Announces Remarkable Data on GNS561 in Combination with anti-PD1 to be Presented at the AACR Annual Meeting 2020
- This In vivo study was performed in a transgenic immunocompetent mouse model of hepatocarcinoma (HCC) using GNS561 alone or in combination with a PD-1 inhibitor
- In addition to good tolerance, GNS561 in combination with a PD-1 inhibitor showed significant antitumoral activity, with a 77% decrease in the macronodule counts compared to control group
- Data shows that GNS561 allows PD-1 inhibitor to recover its antitumoral efficacy by recolonizing the tumoral territories
Marseille, June 15, 2020 – Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and developing anticancer treatment drugs, today announces that its poster demonstrating promising results from a combination study with a PD-1 inhibitor in a transgenic mouse model of hepatocarcinoma (HCC) was selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting being held June 22-24, 2020 in a virtual format only due to COVID-19 worldwide crisis.
This in vivo study was performed the ASV-B transgenic immunocompetent mouse model of HCC. Animals were treated by the vehicle, GNS561 or PD-1 inhibitor as monotherapy or GNS561 in combination with PD-1 inhibitor. Results showed an outstanding anticancer response, with a 59% and 77% decrease of the macronodules count using GNS561 alone and in the combination group compared to controls respectively.
“We are delighted to be presenting this positive in vivo study at the AACR Meeting 2020. These results may open a new horizon in the area of immuno-oncology by enlarging indication of the use of immune checkpoint inhibitors in tumor types that are marginally sensitive to immunotherapy or for patients developing resistance to checkpoint inhibitors. We believe our results provide a strong rationale for combining our drug to a PD-1 inhibitor antibody in clinical trials with HCC patients.” said Pr Eric Raymond, Chief Medical Officer at Genoscience Pharma.
“We are looking forward to assess this combination in HCC patients, for which immunotherapy hasn’t answered the current medical need.”, commented Pr Philippe Halfon, President and Founder of Genoscience Pharma.
The details for the Company’s poster presentation are as follows:
Presenting Author: Dr Madani RACHID, PharmD, MSc.
Poster title: GNS561, A NEW ORAL CLINICAL-STAGE SMALL MOLECULE COMBINED WITH ANTI-PD1 SHOWED REMARKABLE ANTI-TUMOR EFFECTS IN A TRANSGENIC IMMUNOCOMPETENT HEPATOCELLULAR CARCINOMA MOUSE MODEL (ASV-B), Poster 899.
Presentation date and time: June 22, 2020 (from 9 am to 6 pm)